Company Filing History:
2 out of 3,687 
2 out of 2 Years Active: 2021-2023
Title: Eniko Papp: Pioneering Innovations in Cancer Therapy
Introduction
Eniko Papp, an esteemed inventor based in Baltimore, MD, has made significant contributions to the field of cancer research through her patented innovations. With a total of 2 patents to her name, Papp's work addresses critical challenges in understanding and overcoming therapeutic resistance in cancer treatments.
Latest Patents
One of her latest patents, titled "Response to EGFR blockade," delves into the complex genomic landscape associated with human cancers. Recent analyses have highlighted that individuals with the same tumor type can exhibit varied responses to therapies due to underlying genetic differences. In her research, Papp examined somatic genetic changes in colorectal cancer affecting sensitivity to anti-EGFR antibody blockade. This involved complete exome sequencing and copy number analyses of 129 KRAS wild-type tumors. The study revealed several mutations in critical genes such as ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1, which contribute to primary resistance against anti-EGFR therapies. These findings pave the way for combinatorial therapies targeting actionable genes, suggesting new interventions in the management of colorectal cancer.
Career Highlights
Eniko Papp has held notable positions in reputable institutions, including The Johns Hopkins University and University of Torino. Her extensive research is instrumental in refining therapeutic strategies against cancer and enhancing patient outcomes through targeted therapies.
Collaborations
Throughout her career, Papp has collaborated with distinguished colleagues, including Victor E. Velculescu and Vilmos Adleff. These partnerships have been crucial in advancing the understanding of cancer resistance mechanisms and developing innovative treatment approaches.
Conclusion
Eniko Papp's work exemplifies the intersection of innovative research and practical applications in cancer therapy. Her patents and collaborations highlight her commitment to improving therapeutic responses and providing new avenues for treatment. As research in this field evolves, her contributions will undoubtedly continue to influence cancer management strategies for years to come.